Literature DB >> 18622846

3-year follow-up of 215 fracture patients from a prospective and consecutive osteoporosis screening program. Fracture patients care!

Jörgen Astrand1, Karl-Göran Thorngren, Magnus Tägil, Kristina Akesson.   

Abstract

BACKGROUND AND
PURPOSE: Fractures can be prevented if osteoporosis is identified and treated. Starting in 2002, we have been using a screening program in which patients between 50 and 75 years of age with a wrist, shoulder, vertebral, or hip fracture are assessed by DEXA of the hip and spine and if osteoporotic or osteopenic, they are encouraged to see a doctor of their own choice. The patients receive documents containing information, the results of DEXA, and a letter to present to their doctor with suggestions regarding blood tests and treatment. Here we report the 3-year follow-up regarding compliance to the recommended treatment.
METHODS: A questionnaire was sent to fracture patients who participated in the initial screening study from November 2002 through November 2003. Questions included whether they had seen a doctor, whether treatment had been initiated, and their opinions about osteoporosis.
RESULTS: 215 of the 236 patients answered the questionnaire, with a mean follow-up of 39 months. 76/87 of those with osteoporosis, 70/99 of those with osteopenia, and 11/29 of those with normal BMD had seen a doctor. Anti-resorptive treatment was prescribed to two-thirds of the osteoporotic patients, to one-sixth of the osteopenic patients, and to none of the patients with normal bone density. Calcium-vitamin D supplementation as monotherapy was given to one-third of the osteoporotic patients, to half of the osteopenic patients, and to half of the normal patients. Only a few osteoporotic patients, one-third of the osteopenic patients, and half of the normal patients received no treatment. Compliance to treatment was 80% over 3 years in those treated. Most patients felt that they could influence their skeletal health.
INTERPRETATION: Screening of fracture patients for osteoporosis effectively identifies patients with low bone mineral density and the patient can be trusted to seek appropriate medical advice for treatment of osteoporosis. Based on the bone scan diagnosis, the treatment that these patients received reflects current treatment guidelines well.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622846     DOI: 10.1080/17453670710015328

Source DB:  PubMed          Journal:  Acta Orthop        ISSN: 1745-3674            Impact factor:   3.717


  5 in total

Review 1.  A review of patient-centred post-fracture interventions in the context of theories of health behaviour change.

Authors:  R Sujic; M A Gignac; R Cockerill; D E Beaton
Journal:  Osteoporos Int       Date:  2011-01-11       Impact factor: 4.507

2.  Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study.

Authors:  Annie W Kung; Tao Fan; Ling Xu; Wei B Xia; Il Hyung Park; Hak Sun Kim; Siew Pheng Chan; Joon Kiong Lee; Leonard Koh; Yung Kuei Soong; Suppasin Soontrapa; Thawee Songpatanasilp; Thana Turajane; Marc Yates; Shuvayu Sen
Journal:  BMC Womens Health       Date:  2013-02-14       Impact factor: 2.809

3.  Screening for osteoporosis reduced new fracture incidence by almost half: a 6-year follow-up of 592 fracture patients from an osteoporosis screening program.

Authors:  Jörgen Astrand; Johan Nilsson; Karl-Göran Thorngren
Journal:  Acta Orthop       Date:  2012-11-11       Impact factor: 3.717

4.  Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle.

Authors:  K Akesson; D Marsh; P J Mitchell; A R McLellan; J Stenmark; D D Pierroz; C Kyer; C Cooper
Journal:  Osteoporos Int       Date:  2013-04-16       Impact factor: 4.507

5.  Influence of Supplementary Vitamin D on Bone Mineral Density When Used in Combination with Selective Estrogen Receptor Modulators.

Authors:  Hyun Ju Liu; Soo Ah Kim; Da Joung Shim; Ji Min Jung; Eun Jeong Lee
Journal:  J Menopausal Med       Date:  2019-07-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.